Patents Represented by Attorney Bonnie L. Deppenbrock
  • Patent number: 8318940
    Abstract: Compounds of Formula (I), wherein substituents R1, R2 and R5 are as defined, and Ar represents substituted phenyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, thiazolyl, furanyl, imidazolyl and thiophenyl substituted by a hydroxyalkyl substituent and an optional other substituent; compositions containing them, their use in therapy, including their use as antibacterials, for example in the treatment of tuberculosis, and methods for the preparation of such compounds, are provided.
    Type: Grant
    Filed: January 15, 2010
    Date of Patent: November 27, 2012
    Assignee: Glaxo Group Limited
    Inventors: Carlos Alemparte-Gallardo, David Barros-Aguirre, Monica Cacho-Izquierdo, Jose Maria Fiandor Roman, Jose Luis Lavandera Diaz, Modesto Jesús Remuiñan-Blanco
  • Patent number: 8293798
    Abstract: A compound of formula (I) or salts thereof, wherein R1, R2, R3, R4, n and X are as defined in the specification; a process for preparing such compounds, a pharmaceutical composition comprising such compounds; and the use of such compounds in medicine.
    Type: Grant
    Filed: October 30, 2008
    Date of Patent: October 23, 2012
    Assignee: Glaxo Group Limited
    Inventors: Alessandra Gaiba, Susan Roomans, Martin Edward Swarbrick
  • Patent number: 8283474
    Abstract: The present invention relates to novel compounds of formula (I) or a pharmaceutically acceptable salt thereof: wherein G is selected from a group consisting of: phenyl, pyridyl, benzothiazolyl, indazolyl; p is an integer ranging from 0 to 5; R1 is independently selected from a group consisting of: halogen, hydroxy, cyano, C1-4alkyl, haloC1-4alkyl, C1-4alkoxy, haloC1-4alkoxy, C1-4alkanoyl; or corresponds to a group R5; R2 is hydrogen or C1-4alkyl; R3 is C1-4alkyl; R4 is hydrogen, or a phenyl group, a heterocyclyl group, a 5- or 6-membered heteroaromatic group, or a 8- to 11-membered bicyclic group, any of which groups is optionally substituted by 1, 2, 3 or 4 substituents selected from the group consisting of: halogen, cyano, C1-4alkyl, haloC1-4alkyl, C1-4alkoxy, C1-4alkanoyl; R5 is a moiety selected from the group consisting of: isoxazolyl, —CH2—N-pyrrolyl, 1,1-dioxido-2-isothiazolidinyl, thienyl, thiazolyl, pyridyl, 2-pyrrolidinonyl, and such a group is optionally substituted by one or two substituent
    Type: Grant
    Filed: December 16, 2009
    Date of Patent: October 9, 2012
    Assignee: Glaxo Group Limited
    Inventors: Anna Maria Capelli, Giovanna Tedesco
  • Patent number: 8263782
    Abstract: The present invention relates to novel compounds of formula (I) or a pharmaceutically acceptable salt thereof: wherein G is selected from a group consisting of: phenyl, pyridyl, benzothiazolyl, indazolyl; p is an integer ranging from 0 to 5; R1 is independently selected from a group consisting of: halogen, hydroxy, cyano, C1-4alkyl, haloC1-4alkyl, C1-4alkoxy, haloC1-4alkoxy, C1-4alkanoyl; or corresponds to a group R5; R2 is hydrogen or C1-4alkyl; R3 is C1-4alkyl; R4 is hydrogen, or a phenyl group, a heterocyclyl group, a 5- or 6-membered heteroaromatic group, or a 8- to 11-membered bicyclic group, any of which groups is optionally substituted by 1, 2, 3 or 4 substituents selected from the group consisting of: halogen, cyano, C1-4alkyl, haloC1-4alkyl, C1-4alkoxy, C1-4alkanoyl; R5 is a moiety selected from the group consisting of: isoxazolyl, —CH2—N-pyrrolyl, 1,1-dioxido-2-isothiazolidinyl, thienyl, thiazolyl, pyridyl, 2-pyrrolidinonyl, and such a group is optionally substituted by one or two substituent
    Type: Grant
    Filed: December 16, 2009
    Date of Patent: September 11, 2012
    Assignee: Glaxo Group Limited
    Inventors: Luca Arista, Giorgio Bonanomi, Gabriella Gentile, Dieter Hamprecht, Fabrizio Micheli, Anna Maria Capelli, Federica Damiani, Romano Di Fabio, Luca Tarsi, Giovanna Tedesco, Silvia Terreni
  • Patent number: 8222261
    Abstract: The present invention relates to novel compounds that are useful in the treatment of metabolic disorders, particularly Type II diabetes mellitus and related disorders, and also to the methods for the making and use of such compounds.
    Type: Grant
    Filed: January 13, 2009
    Date of Patent: July 17, 2012
    Assignee: GlaxoSmithKline, LLC
    Inventors: Subba R Katamreddy, Richard Dama Caldwell, Dennis Heyer, Vincente Samano, James Benjamin Thompson, Andrew J Carpenter, Christopher R Conlee, Eric Eugene Boros, Brian D Thompson
  • Patent number: 8222266
    Abstract: The present invention relates to certain azabicyclo compounds of formula (I)?: wherein the various groups are defined herein and that are modulators of dopamine D3 receptors, e.g. to treat drug dependency, as antipsychotic agents, to treat obsessive compulsive spectrum disorders, or premature ejaculation.
    Type: Grant
    Filed: March 30, 2007
    Date of Patent: July 17, 2012
    Assignee: Glaxo Group Limited
    Inventors: Barbara Bertani, Anna Checchia, Romano Di Fabio, Gabriella Gentile, Fabrizio Micheli, Alessandra Pasquarello, Silvia Terreni
  • Patent number: 8217168
    Abstract: The present invention relates to novel compounds of formula (I) or a salt thereof: wherein G is selected from a group consisting of: phenyl, a 5- or 6-membered monocyclic heteroaryl group, or a 8- to 11-membered heteroaryl bicyclic group; p is an integer ranging from 0 to 5; R1 is halogen, hydroxy, cyano, C1-4alkyl, haloC1-4alkyl, C1-4alkoxy, haloC1-4alkoxy, C1-4alkanoyl and SF5; or corresponds to a group R6; and when p is an integer ranging from 2 to 5, each R1 may be the same or different; R2 is hydrogen or C1-4alkyl; n is 3, 4, 5 or 6; R6 is a moiety selected from the group consisting of: isoxazolyl, —CH2—N-pyrrolyl, 1,1-dioxido-2-isothiazolidinyl, thienyl, thiazolyl, pyridyl, 2-pyrrolidinonyl, and such R6 group is optionally substituted by one or two substituents selected from: halogen, cyano, C1-4alkyl, haloC1-4alkyl, C1-4alkoxy, C1-4alkanoyl; R4 is selected in the group consisting of: hydrogen, halogen, hydroxy, cyano, C1-4alkyl, C3-7 cycloalkyl, haloC1-4alkyl, C1-4alkoxy, haloC1-4alkoxy, C1-4alkan
    Type: Grant
    Filed: October 1, 2008
    Date of Patent: July 10, 2012
    Assignee: Glaxo Group Limited
    Inventors: Barbara Bertani, Susanna Cremonesi, Stefano Fontana, Alessandra Pasquarello
  • Patent number: 8178549
    Abstract: The present invention relates to novel compounds of formula (I) or a salt thereof: wherein R1 is a 5-membered heteroaryl group, optionally fused with a 6-membered hetero or carbocycle; such 5 or 11-membered system, may be optionally substituted by 1, 2, 3 or 4 substituents selected from the group consisting of: halogen, cyano, C1-4alkyl, haloC1-4alkyl, C1-4alkoxy, C1-4alkanoyl, haloC1-4alkoxy and SF5; and n is 1 or 2; their use in therapy, as modulators of dopamine D3 receptors, e.g. to treat drug dependency, as antipsychotic agents, to treat obsessive compulsive spectrum disorders, or premature ejaculation.
    Type: Grant
    Filed: October 1, 2008
    Date of Patent: May 15, 2012
    Assignee: Glaxo Group Limited
    Inventors: Barbara Bertani, Francesca Cardullo, Paolo Dambruoso, Paola Marzorati, Fabrizio Micheli, Alessandra Pasquarello, Catia Seri, Giovanna Tedesco
  • Patent number: 8173820
    Abstract: Compounds of formula (I) and salts thereof are provided: wherein n is 0, 1, 2 or 3; R1 is selected from phenyl and pyridyl, each of which is optionally substituted by one or two groups independently selected from C1-4alkyl and halogen; and R2 is selected from H and CH3 when n is 1 and R2 is H when n is 2 or 3. Processes for preparation, pharmaceutical compositions, and uses thereof as a medicament, for example in the treatment of a disease or condition mediated by a reduction or imbalance in glutamate receptor function, such as schizophrenia or cognition impairment, are also disclosed.
    Type: Grant
    Filed: December 17, 2008
    Date of Patent: May 8, 2012
    Assignee: Glaxo Group Limited
    Inventors: Nicolas Bertheleme, Wai Ngor Chan, Jaqueline Sandra Scott, Simon E. Ward
  • Patent number: 8163927
    Abstract: The present invention relates to certain azabicyclic compounds of formula (I)?: wherein the several groups are defined herein and are modulators of dopamine D3 receptors, e.g. to treat drug dependency, as antipsychotic agents, to treat obsessive compulsive spectrum disorders, or premature ejaculation.
    Type: Grant
    Filed: March 30, 2007
    Date of Patent: April 24, 2012
    Assignee: Glaxo Group Limited
    Inventors: Barbara Bertani, Fabrizio Micheli, Alessandra Pasquarello, Silvia Terreni
  • Patent number: 8101634
    Abstract: The present invention relates to novel compounds that are useful in the treatment of metabolic disorders, particularly type II diabetes mellitus and related disorders, and also to the methods for the making and use of such compounds.
    Type: Grant
    Filed: December 5, 2007
    Date of Patent: January 24, 2012
    Assignee: GlaxoSmithKline LLC
    Inventors: Jing Fang, Jun Tang, Andrew J Carpenter, Gregory Peckham, Christopher R Conlee, Kien S Du, Subba Reddy Katamreddy
  • Patent number: 8097628
    Abstract: Compounds of Formula (I) or pharmaceutically acceptable salts or N-oxides thereof: (relative chemistry shown) pharmaceutical compositions comprising them, their use in therapy especially against tuberculosis, and methods of preparing them are described.
    Type: Grant
    Filed: May 21, 2009
    Date of Patent: January 17, 2012
    Assignee: Glaxo Group Limited
    Inventors: Carlos Alemparte-Gallardo, Christopher Barfoot, David Barros-Aguirre, Monica Cacho-Izquierdo, Jose Maria Fiandor Roman, Alan Joseph Hennessy, Neil David Pearson, Modesto Jesus Remuinan-Blanco
  • Patent number: 8088779
    Abstract: The present invention generally relates to the polymorph Form 2 of [3-(4-methoxy-2-methyl-phenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidin-7-yl]-[(S)-1-(3-methyl-[1,2,4]oxa-diazol-5-yl)-propyl]amine. The present invention also relates to pharmaceutical compositions comprising the same and methods of using the same.
    Type: Grant
    Filed: September 28, 2006
    Date of Patent: January 3, 2012
    Assignee: SmithKline Beecham (Cork) Limited
    Inventor: Frank Hossner
  • Patent number: 8030322
    Abstract: The present invention relates to compounds of formula (I) or salts thereof wherein A, X, R2, R4 and n are defined herein, processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them and their use in therapy, as modulators of dopamine D3 receptors, e.g., to treat drug dependency, as antipsychotic agents, to treat obsessive compulsive spectrum disorders, premature ejaculation or to enhance cognition.
    Type: Grant
    Filed: April 24, 2007
    Date of Patent: October 4, 2011
    Assignee: Glaxo Group Limited
    Inventors: Barbara Bertani, Romano Di Fabio, Fabrizio Micheli, Alessandra Pasquarello, Luca Tarsi, Silvia Terreni
  • Patent number: 8026270
    Abstract: The present invention relates to naphthalene derivatives, to processes for their preparation, to pharmaceutical compositions containing them and to their use in medicine.
    Type: Grant
    Filed: July 26, 2007
    Date of Patent: September 27, 2011
    Assignee: Glaxo Group Limited
    Inventors: Gerard Martin Paul Giblin, Mark Patrick Healy, Helen Susanne Price
  • Patent number: 7989444
    Abstract: Compounds of formula (I) wherein A is a 5 or 6 membered heteroaromatic ring or a 5 or 6 membered heterocyclic ring, and which are useful for treating mental disorders such as schizophrenia are set out herein.
    Type: Grant
    Filed: May 31, 2005
    Date of Patent: August 2, 2011
    Assignee: Glaxo Group Limited
    Inventors: Giorgio Bonanomi, Federica Damiani, Gabriella Gentile, Dieter Wolfgang Hamprecht, Fabrizio Micheli, Luca Tarsi, Giovanna Tedesco, Silvia Terreni
  • Patent number: 7947683
    Abstract: The present invention relates to novel compounds of formula (I) or pharmaceutically acceptable salt thereof: processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them and their use in therapy, as modulators of dopamine D3 receptors, e.g. to treat drug dependency, as antipsychotic agents, to treat obsessive compulsive spectrum disorders, premature ejaculation or cognition impairment.
    Type: Grant
    Filed: April 12, 2006
    Date of Patent: May 24, 2011
    Assignee: Glaxo Group Limted
    Inventors: Giorgio Bonanomi, Anna Checchia, Elettra Fazzolari, Dieter Hamprecht, Fabrizio Micheli, Luca Tarsi, Silvia Terreni
  • Patent number: 7846922
    Abstract: The present invention relates to novel diazepanyl derivatives of formula (I) having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of neurological and psychiatric disorders.
    Type: Grant
    Filed: October 14, 2004
    Date of Patent: December 7, 2010
    Assignee: Glaxo Group Limited
    Inventors: Gordon Bruton, Anthony Huxley, Barry Sidney Orlek, Kishore Kalidas Rana
  • Patent number: 7834013
    Abstract: The present invention relates generally to novel therapeutic compounds and more particularly to novel compounds, their use as GPR40 agonists, processes for their manufacture, and intermediates useful in their preparation.
    Type: Grant
    Filed: November 15, 2004
    Date of Patent: November 16, 2010
    Assignee: GlaxoSmithKline LLC
    Inventors: David Francis Corbett, Kate Anna Dwornik, Dulce Maria Garrido, Stephen Carl McKeown, Wendy Yoon Mills, Andrew James Peat, Terrence Lee Smalley, Jr.
  • Patent number: 7759369
    Abstract: Compounds of formula (I) or a pharmaceutically acceptable derivative thereof: wherein X, Y, Z, R2a, R2b, R3a, R3b, R8, R9, and Rx are as defined in the specification, a process for the preparation of such compounds, pharmaceutical compositions comprising such compounds and the use of such compounds in medicine.
    Type: Grant
    Filed: June 21, 2007
    Date of Patent: July 20, 2010
    Assignee: Glaxo Group Limited
    Inventors: Gerard Martin Paul Giblin, Adrian Hall